Current knowledge about FLT3 gene mutations, exploring the isoforms, and protein importance in AML

Macečková, Diana; Vaňková, Lenka; Holubová, Monika; Jindra, Pavel; Klieber, Robin; Jandová, Eliška; Pitule, Pavel

doi:10.1007/s11033-024-09452-2

Mol Biol Rep

2024

DOI: 10.1007/s11033-024-09452-2

|View full text |Cite

Current knowledge about FLT3 gene mutations, exploring the isoforms, and protein importance in AML

Diana Macečková,

Lenka Vaňková,

Monika Holubová

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 97 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Common Driver Mutations in AML: Biological Impact, Clinical Considerations, and Treatment Strategies

Nong,

Mehra,

Taylor

2024

Cells

View full text Add to dashboard Cite

Next-generation sequencing of samples from patients with acute myeloid leukemia (AML) has revealed several driver gene mutations in adult AML. However, unlike other cancers, AML is defined by relatively few mutations per patient, with a median of 4–5 depending on subtype. In this review, we will discuss the most common driver genes found in patients with AML and focus on the most clinically relevant ones that impact treatment strategies. The most common driver gene mutations in AML occur in NPM1 and FLT3, accounting for ~30% each. There are now targeted therapies being tested or already approved for these driver genes. Menin inhibitors, a novel targeted therapy that blocks the function of the menin protein, are in clinical trials for NPM1 driver gene mutant AML after relapse. A number of FLT3 inhibitors are now approved for FLT3 driver gene mutant AML in combination with chemotherapy in the frontline and also as single agent in relapse. Although mutations in IDH1/2 and TP53 only occur in around 10–20% of patients with AML each, they can affect the treatment strategy due to their association with prognosis and availability of targeted agents. While the impact of other driver gene mutations in AML is recognized, there is a lack of data on the actionable impact of those mutations.

show abstract

Common Driver Mutations in AML: Biological Impact, Clinical Considerations, and Treatment Strategies

Nong,

Mehra,

Taylor

2024

Cells

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Current knowledge about FLT3 gene mutations, exploring the isoforms, and protein importance in AML

Cited by 1 publication

References 97 publications

Common Driver Mutations in AML: Biological Impact, Clinical Considerations, and Treatment Strategies

Common Driver Mutations in AML: Biological Impact, Clinical Considerations, and Treatment Strategies

Contact Info

Product

Resources

About